Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients with unresectable or metastatic HER2-negative gastric or ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

BeiGene (BGNE), a global oncology company that intends to change its name to BeOne Medicines, announced the U.S. FDA has approved Tevimbra in ...

SAN MATEO, Calif., December 27, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in combination with chemotherapy to treat advanced gastric or gastroesophageal ...